Forteo

Forteo is a brand name of teriparatide, approved by the FDA in the following formulation(s):

FORTEO (teriparatide recombinant human - injectable; subcutaneous)

• 
  Manufacturer: LILLY
  
  Approval date: June 25, 2008
  
  Strength(s): 0.6MG/2.4ML (0.25MG/ML) ^[RLD]

Has a generic version of Forteo been approved?

No. There is currently no therapeutically equivalent version of Forteo available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Forteo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Stabilized teriparatide solutions
  Patent 6,770,623
  Issued: August 3, 2004
  Inventor(s): Chin-Ming; Chang & Henry A.; Havel
  Assignee(s): Eli Lilly and Company
  A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1-34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.
  
  Patent expiration dates:
  
  
  • December 8, 2018
    
    ✓ 
    Patent use: FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
    ✓ 
    Drug product
  
  
  
  • December 8, 2018
    
    ✓ 
    Patent use: A METHOD OF TREATING OSTEOPOROSIS
    ✓ 
    Drug product
  
  



• 
  Method of increasing bone toughness and stiffness and reducing fractures
  Patent 6,977,077
  Issued: December 20, 2005
  Inventor(s): Hock; Janet M. & Gaich; Gregory A. & Dere; Willard H.
  Assignee(s): Eli Lilly and Company
  The invention relates to a method for increasing the toughness and/or stiffness of bone and/or reducing the likelihood and/or severity of bone fracture by administering a parathyroid hormone. The method can be employed to increase toughness or stiffness of bone at a site of a potential or actual trauma, such as the hip or spine of a person at risk of or suffering from osteoporosis. The method of the invention can reduce the incidence of vertebral fracure, reduce the incidence of multiple vertebral fractures, reduce the severity of vertebral fracture, and/or reduce the incidence of non-vertebral fracture.
  
  Patent expiration dates:
  
  
  • August 19, 2019
    
    ✓ 
    Patent use: FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
  
  
  
  • August 19, 2019
    
    ✓ 
    Patent use: A METHOD OF TREATING OSTEOPOROSIS
  
  
  
  • August 19, 2019
    
    ✓ 
    Patent use: METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED
  
  



• 
  Stabilized teriparatide solutions
  Patent 7,144,861
  Issued: December 5, 2006
  Inventor(s): Chang; Chin-Ming & Havel; Henry A.
  Assignee(s): Eli Lilly and Company
  A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1–34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.
  
  Patent expiration dates:
  
  
  • December 8, 2018
    
    ✓ 
    Drug product
  
  



• 
  Method of increasing bone toughness and stiffness and reducing fractures
  Patent 7,163,684
  Issued: January 16, 2007
  Inventor(s): Gaich; Gregory A. & Dere; Willard H. & Hock; Janet M.
  Assignee(s): Eli Lilly and Company
  The invention relates to a method for increasing the toughness and/or stiffness of bone and/or reducing the likelihood and/or severity of bone fracture by administering a parathyroid hormone. The method can be employed to increase toughness or stiffness of bone at a site of a potential or actual trauma, such as the hip or spine of a person at risk of or suffering from osteoporosis. The method of the invention can reduce the incidence of vertebral fracture, reduce the incidence of multiple vertebral fractures, reduce the severity of vertebral fracture, and/or reduce the incidence of non-vertebral fracture.
  
  Patent expiration dates:
  
  
  • August 19, 2019
    
    ✓ 
    Patent use: FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS
  
  
  
  • August 19, 2019
    
    ✓ 
    Patent use: METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED
  
  
  
  • August 19, 2019
    
    ✓ 
    Patent use: METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE
  
  



• 
  Method of reducing the risk of bone fracture
  Patent 7,351,414
  Issued: April 1, 2008
  Inventor(s): Gaich; Gregory A. & Dere; Willard H. & Hock; Janet M.
  Assignee(s): Eli Lilly and Company
  The invention relates to a method for increasing the toughness and/or stiffness of bone and/or reducing the likelihood and/or severity of bone fracture by administering a parathyroid hormone. The method can be employed to increase toughness or stiffness of bone at a site of a potential or actual trauma, such as the hip or spine of a person at risk of or suffering from osteoporosis. The method of the invention can reduce the incidence of vertebral fracture, reduce the incidence of multiple vertebral fractures, reduce the severity of vertebral fractur and/or reduce the incidence of non-vertebral fracture.
  
  Patent expiration dates:
  
  
  • August 19, 2019
    
    ✓ 
    Patent use: TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE
  
  
  
  • August 19, 2019
    
    ✓ 
    Patent use: METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED
  
  
  
  • August 19, 2019
    
    ✓ 
    Patent use: METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE
  
  



• 
  Stabilized teriparatide solutions
  Patent 7,550,434
  Issued: June 23, 2009
  Inventor(s): Chang; Chin-Ming & Havel; Henry A.
  Assignee(s): Eli Lilly and Company
  A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1-34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.
  
  Patent expiration dates:
  
  
  • December 8, 2018
    
    ✓ 
    Patent use: A METHOD OF TREATING OSTEOPOROSIS
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • July 22, 2012 - TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE
  
  

See also...

• Forteo Consumer Information (Drugs.com)
• Forteo Consumer Information (Wolters Kluwer)
• Forteo Consumer Information (Cerner Multum)
• Forteo Advanced Consumer Information (Micromedex)
• Forteo AHFS DI Monographs (ASHP)
• Teriparatide Consumer Information (Wolters Kluwer)
• Teriparatide Consumer Information (Cerner Multum)
• Teriparatide Subcutaneous Advanced Consumer Information (Micromedex)
• Teriparatide AHFS DI Monographs (ASHP)